Stichworte
Hepatitis C ×
Zeige mehr Stichworte
Inhaltsverzeichnis
  1. 1. Klinische Studie
  2. 2. Routinedokumentation
  3. 3. Register-/Kohortenstudien
  4. 4. Qualitätssicherung
  5. 5. Datenstandard
  6. 6. Patientenfragebogen
  7. 7. Medizinische Fachrichtung
Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

121 Suchergebnisse.

Effect of inhaled Fluticasone furoate and cellobiose octa-acetate on electrocardiographic parameters in healthy subjects, Study-ID: 101888 - Serology - screen for HIV antibody, hepatitis B and C

- 04.02.19 - 1 Formular, 2 Itemgruppen, 4 Datenelemente, 1 Sprache
Itemgruppen: Administrative data, Serology - screen for HIV antibody, hepatitis B and C
Study ID: 101888 Clinical Study ID: FFR101888 Study Title: A randomised, placebo-controlled, four way crossover study to evaluate the effect of double-blind 4000 mcg of orally inhaled GW685698X and of 6.25 mg cellobiose octa-acetate on electrocardiographic parameters, with single-blind 400 mg of oral moxifloxacin as a positive control, in 40 healthy male and female subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone furoate Trade Name: Veramyst,Avamys,Allermist Study Indication: Rhinitis, Allergic, Perennial The study consists of a screening, 4 treatment periods (TP) and a follow-up visit. For each TP there is a Day-1 (D-1) and a Day1 (D1). This document contains the Serology - screen for HIV antibody, hepatitis B and C form. It has to be filled in for screening.

Eligibility Hepatitis C, Chronic NCT01147107

- 16.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection; ODM derived from: https://clinicaltrials.gov/show/NCT01147107

Eligibility Hepatitis C, Chronic NCT01057667

- 16.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4; ODM derived from: https://clinicaltrials.gov/show/NCT01057667

Eligibility Hepatitis C Virus NCT01170962

- 16.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment; ODM derived from: https://clinicaltrials.gov/show/NCT01170962

Eligibility Hepatitis C Virus NCT01125189

- 16.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Study of BMS-790052 Add-On to Standard of Care in Treatment Naive Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT01125189

Eligibility Hepatitis C Virus (HCV) NCT01754974

- 16.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C; ODM derived from: https://clinicaltrials.gov/show/NCT01754974

Eligibility Hepatitis C NCT02485262

- 16.01.19 - 1 Formular, 2 Itemgruppen, 10 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience; ODM derived from: https://clinicaltrials.gov/show/NCT02485262

Eligibility Hepatitis C NCT00911963

- 16.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection; ODM derived from: https://clinicaltrials.gov/show/NCT00911963

Eligibility Hepatitis C (HCV) NCT01750515

- 16.01.19 - 1 Formular, 2 Itemgruppen, 11 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Acupuncture as an Adjunctive Treatment for Hepatitis C Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01750515

Eligibility Hepatitis C Virus Infection NCT01718145

- 02.01.19 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT01718145

Eligibility Hepatitis C NCT02175966

- 28.12.18 - 1 Formular, 3 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Criteria, Inclusion Criteria, Exclusion Criteria
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study); ODM derived from: https://clinicaltrials.gov/show/NCT02175966

Eligibility Hepatitis C NCT01795911

- 28.12.18 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin; ODM derived from: https://clinicaltrials.gov/show/NCT01795911